Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10639592 | 0.77 | TSHR (0.36) | TSHRLTA4HMAOBALDH1A1KIF11 | |
| SCHEMBL2401039 | 0.77 | LMNA (0.43) | LMNAKMT2A | |
| SCHEMBL10618581 | 0.76 | TSHR (0.39) | TSHRLMNAGAAKMT2ALTA4H | |
| SCHEMBL9550318 | 0.73 | CA4 (0.39) | TSHRLMNAGAAKMT2ALTA4H | |
| SCHEMBL6210928 | 0.73 | CA4 (0.39) | TSHRLMNAGAAKMT2ALTA4H | |
| Water SCHEMBL2397104 | 0.72 | ALDH1A1 (0.42) | LMNAGAAKMT2AMAOBALDH1A1 | |
| SCHEMBL168125 | 0.72 | KIF11 (0.47) | TSHRKMT2ALTA4HKIF11 | |
| SCHEMBL11512563 | 0.71 | TSHR (0.37) | TSHRLMNAGAAKMT2ALTA4H | |
| Fluoride SCHEMBL28371495 | 0.70 | KIF11 (0.46) | TSHRKMT2ALTA4HKIF11 | |
| SCHEMBL29087324 | 0.70 | KIF11 (0.46) | TSHRKMT2ALTA4HKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4531919-A1 | METHOD OF TREATING VITILIGO WITH INTERFERON-GAMMA ANTIBODY | Elixiron Immunotherapeutics (Hong Kong) Limited (HK) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023235830-A1 | METHOD OF TREATING VITILIGO WITH INTERFERON-GAMMA ANTIBODY | ELIXIRON IMMUNOTHERAPEUTICS (HONG KONG) (CN) | 2023-12-07 | — | — | WO | disclosed |
| US-9951366-B2 | Cell-free protein synthesis method and device using a eukaryotic cell lysate in the presence of a caspase inhibitor and the use of a caspase inhibitor for increasing the yield and/or the stability of the synthesized proteins in such a method | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) | 2018-04-24 | — | — | US | disclosed |
| US-20160251692-A1 | CELL-FREE PROTEIN SYNTHESIS METHOD AND DEVICE USING A EUKARYOTIC CELL LYSATE IN THE PRESENCE OF A CASPASE INHIBITOR AND THE USE OF A CASPASE INHIBITOR FOR INCREASING THE YIELD AND/OR THE STABILITY OF THE SYNTHESIZED PROTEINS IN SUCH A METHOD | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) | 2016-09-01 | — | — | US | disclosed |
| EP-3049530-A2 | METHOD AND DEVICE FOR CELL-FREE PROTEIN SYNTHESIS IN THE PRESENCE OF A CASPASE INHIBITOR | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung E.V. (DE) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015043729-A2 | CELL-FREE PROTEIN SYNTHESIS METHOD AND DEVICE USING A EUKARYOTIC CELL LYSATE IN THE PRESENCE OF A CASPASE INHIBITOR, AND THE USE OF A CASPASE INHIBITOR FOR INCREASING THE YIELD AND/OR THE STABILITY OF THE SYNTHESIZED PROTEINS IN SUCH A METHOD | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2015-04-02 | — | — | WO | disclosed |
| WO-2011137485-A1 | MEDIA AND METHODS FOR CELL CULTURE | SYDNEY IVF LIMITED (AU) | 2011-11-10 | — | — | WO | disclosed |